Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
Orhan Aktaş(Heinrich Heine University Düsseldorf), Bruce Cree(University of California, San Francisco), Eliezer Katz, William A. Rees(Mayo Clinic), Gary Cutter(Epilepsy Foundation), Brian G. Weinshenker(Mayo Clinic in Arizona), Friedemann Paul(Max Delbrück Center), Hans‐Peter Hartung(The University of Sydney), Kazuo Fujihara(Tohoku University), Michele Gunsior(Integrated BioTherapeutics (United States)), Sean J. Pittock(Mayo Clinic), Romain Marignier(Hospices Civils de Lyon), Ho Jin Kim(National Cancer Center), Michael Smith(Amgen (United States)), Dewei She, Dean M. Wingerchuk(WinnMed), Daniel Cimbora, Jeffrey L. Bennett(University of Colorado Denver)
Cited by 47
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k